FEMY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	101 776
Average Volume	742 766
Market Cap	29.39M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.220 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.00300 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Spector Richard D.	Buy	100 000	Stock Option (Right to Buy)
2024-02-12	Spector Richard D.	Buy	0
2024-02-01	Currie Daniel Scott	Buy	61 900	Stock Option (Right to Buy)
2024-02-01	Elefant Dov	Buy	84 000	Stock Option (Right to Buy)
2024-02-01	Thomas Christine E	Buy	32 600	Stock Option (Right to Buy)

INSIDER POWER
-78.92
Last 82 transactions
Buy: 6 908 475 \| Sell: 19 734 221

Volume Correlation

Long: -0.22 (neutral)

Short: 0.49 (neutral)

Signal:(55.561) Neutral

Femasys Inc. Correlation

10 Most Positive Correlations
RMRM	0.863
NTEC	0.862
SQBG	0.806

10 Most Negative Correlations
NETE	-0.826

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Femasys Inc. Correlation - Currency/Commodity

0.51
( weak )

0.12
( neutral )

0.00
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.21
( neutral )

Femasys Inc. Financials

Annual	2023
Revenue:	$1.07M
Gross Profit:	$-216 084 (-20.16 %)
EPS:	$-0.930

Q4	2023
Revenue:	$213 111
Gross Profit:	$-107 327 (-50.36 %)
EPS:	$-0.200

Q3	2023
Revenue:	$244 361
Gross Profit:	$158 175 (64.73 %)
EPS:	$-0.260

Q2	2023
Revenue:	$320 514
Gross Profit:	$210 045 (65.53 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Femasys Inc.

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.